Prof. Dr. Ersin Özaslan
Medical Oncology- 2016 – Erciyes University, Faculty of Medicine
Medical Oncology Specialization - 2012 – Erciyes University, Faculty of Medicine
Internal Medicine Specialization - 2007 – Istanbul University, Istanbul Faculty of Medicine
Doctor of Medicine (M.D.)
Prof. Dr. Ersin Özaslan
Medical Oncology- 2018 – Present – Acıbadem Healthcare Group
Medical Oncology Specialist - 2016 – 2018 – Kayseri Training and Research Hospital
Medical Oncology Clinic
Prof. Dr. Ersin Özaslan
Medical Oncology- Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer
Journal of BUON, 2017; 22(4): 863–868. - Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
Journal of Chemotherapy, 2016; 28(3): 230–234. - Psychological distress and loneliness in caregiver of advanced oncological inpatients
Journal of Health Psychology, 2016; 21(9): 1896–1906. - Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors
European Journal of Gastroenterology & Hepatology, 2016; 28(7): 836–841. - Hepatic steatosis is associated with higher incidence of liver metastasis in patients with metastatic breast cancer
Journal of BUON, 2015; 20(4): 963–969. - Predictive significance of VEGF and HIF-1α expression in patients with metastatic colorectal cancer receiving chemotherapy combinations with bevacizumab
Asian Pacific Journal of Cancer Prevention, 2015; 16(14): 6149–6154. - Predicting the role of the pretreatment neutrophil to lymphocyte ratio in the survival of early triple-negative breast cancer patients
Journal of BUON, 2015; 20(6): 1432–1439. - Is late recurrence a predictive clinical marker for better sunitinib response in metastatic renal cell carcinoma patients?
Clinical Genitourinary Cancer, 2015; 13(6): 548–554. - Positive effects of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy
Asian Pacific Journal of Cancer Prevention, 2014; 15(8): 3641–3644. - Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer
Asian Pacific Journal of Cancer Prevention, 2014; 15(6): 2501–2504.